News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Tobira Therapeutics Inc. Reports Encouraging Pharmacokinetic, Bioavailability and Safety Results from Studies of Cenicriviroc



3/1/2011 9:19:59 AM

MANALAPAN, N.J. & BOSTON--(BUSINESS WIRE)--Tobira Therapeutics reported today that single-dose oral administration of cenicriviroc showed predictable pharmacokinetics, good oral bioavailability and no dose-limiting toxicity in both healthy human volunteers and animal models. Cenicriviroc (TBR-652) is a potent antagonist of both CCR5, a co-receptor required for HIV infection, and CCR2, a co-receptor that is prominently involved in a number of metabolic and cardiovascular diseases. Cenicriviroc is currently in Phase 2 clinical development for the treatment of individuals with HIV infection.

Read at BioSpace.com

Related News

comments powered by Disqus
   
HIV/AIDS

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES